experspadmin

Clinical Significance of Improved Bruton Tyrosine Kinase Inhibitor Selectivity
Oncology

Clinical Significance of Improved Bruton Tyrosine Kinase Inhibitor Selectivity

clinical topic updates
By John C. Byrd, MD
Expert Perspectives in Tuberous Sclerosis Complex to Cover Key Topics in Tuberous Sclerosis Complex Treatment
Neurology

Expert Perspectives in Tuberous Sclerosis Complex to Cover Key Topics in Tuberous Sclerosis Complex Treatment

expert perspectives
By David N. Franz, MD; Elizabeth A. Thiele, MD, PhD; Gary W. Mathern, MD
Expert Perspectives in Carcinoid Syndrome to Cover Key Topics in Carcinoid Syndrome Treatment
Oncology

Expert Perspectives in Carcinoid Syndrome to Cover Key Topics in Carcinoid Syndrome Treatment

expert perspectives
By Jonathan R. Strosberg, MD; Lowell B. Anthony, MD, FACP; Timothy J. Hobday, MD
Immune Function, Vaccinations, and Infection Risk in Chronic Lymphocytic Leukemia
Oncology

Immune Function, Vaccinations, and Infection Risk in Chronic Lymphocytic Leukemia

patient care perspectives
By Ian W. Flinn, MD, PhD
Relapse After Venetoclax Plus Obinutuzumab in Chronic Lymphocytic Leukemia
Oncology

Relapse After Venetoclax Plus Obinutuzumab in Chronic Lymphocytic Leukemia

patient care perspectives
By Ian W. Flinn, MD, PhD
Load More